SBIR Phase II: Enabling Technologies for Noninvasive Oxygen Imaging in Regenerative Medicine

SBIR 第二阶段：再生医学中无创氧成像的使能技术

• 批准号: 2028829
• 负责人: Mrignayani Kotecha
• 金额: $ 98.27万
• 依托单位: O2M Technologies, LLC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2028829&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Enabling; Technologies

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will address a major hindrance in developing efficient artificial tissues and organs designed to solve multiple health issues. Currently, poor oxygen and nutrient delivery at the core of the artificial tissues is one of the major causes of graft implantation failure. The public health benefit of replacing damaged tissues and organs is at par with curing cancer. Almost every part of the human body has been considered a candidate for tissue engineering that strives to solve many medical problems such as arthritis, Type I diabetes, stroke, vascular diseases, liver and kidney damages, etc. The technologies developed in this project will assist in the quality control of artificial tissues. This project will serve the preclinical imaging market with a dedicated oxygen imaging instrument. This Small Business Innovation Research (SBIR) Phase II project will develop technologies to address a significant shortcoming in developing artificial tissue grafts and organs. Tissue engineering regenerative medicine (TERM) is the fastest growing branch of medicine. TERM aims at the replacement or regeneration of damaged cells, tissues, or organs with artificial cell replacement devices, tissue grafts or organs, to restore normal biological function. However, the dream of artificial tissue has not been realized because of the lack of technologies that can provide maps of physiological parameters such as oxygen. The project will develop new enabling technologies for oxygen imaging in biomaterials, multi-well plate, and macro-encapsulation devices. The project will also manufacture the oxygen sensitive spin probe. It is expected that three-dimensional noninvasive oxygen imaging of tissue grafts and cell encapsulation devices will pave the way for off-the-shelf artificial tissue grafts and organs and make tissue manufacturing a reality.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究（SBIR）第二阶段项目的更广泛的影响/商业潜力将解决开发旨在解决多种健康问题的有效人工组织和器官的主要障碍。目前，人工组织核心的氧气和营养输送不足是移植物植入失败的主要原因之一。更换受损组织和器官的公共卫生效益与治愈癌症不相上下。人体几乎每个部位都被认为是组织工程的候选对象，致力于解决关节炎、I型糖尿病、中风、血管疾病、肝肾损伤等许多医疗问题。本项目开发的技术将有助于人工组织的质量控制。该项目将为临床前成像市场提供专用氧气成像仪器。这个小企业创新研究（SBIR）第二阶段项目将开发技术，以解决开发人工组织移植物和器官的重大缺陷。组织工程再生医学（$TERM）是发展最快的医学分支。$TERM旨在用人工细胞替代装置、组织移植物或器官替代或再生受损的细胞、组织或器官，以恢复正常的生物功能。然而，由于缺乏能够提供氧气等生理参数图谱的技术，人造组织的梦想一直没有实现。该项目将开发新的使能技术，用于生物材料、多孔板和宏观封装设备中的氧成像。该项目还将制造氧敏自旋探针。预计组织移植物和细胞封装装置的三维无创氧气成像将为现成的人造组织移植物和器官铺平道路，并使组织制造成为现实。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。